Hepatology

Article	Citations
Epidemiology of Hepatocellular Carcinoma	1151
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review	775
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	696
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	610
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	389
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases	352
Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases	336
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma	332
From NAFLD to MAFLD: Implications of a Premature Change in Terminology	270
Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study	268
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future	241
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade	220
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma	213
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial	209
Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides	180
Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression	175
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis	173
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH	173
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC	171
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma	160
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases	148
Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study	147
Liver Biochemistries in Hospitalized Patients With COVID‐19	142
High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population	142
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder	142

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement	138
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	133
Emerging immunotherapy for HCC: A guide for hepatologists	125
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH	125
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	123
The Tumor Microenvironment in Cholangiocarcinoma Progression	117
Myeloid‐Cell–Specific IL‐6 Signaling Promotes MicroRNA‐223‐Enriched Exosome Production to Attenuate NAFLD‐Associated Fibrosis	116
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD	115
Microbiota‐Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling	115
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease	114
Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases	113
Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis	113
A Circular RNA, Cholangiocarcinoma‐Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers	111
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	111
Biomarkers for Hepatobiliary Cancers	107
Surgical Treatments of Hepatobiliary Cancers	106
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma	105
Global burden of NAFLD and chronic liver disease among adolescents and young adults	104
HBV‐Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC	100
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	99
Osteopontin Takes Center Stage in Chronic Liver Disease	99
Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis	99
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study	98
Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice	98
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?	97
NAFLD: Reporting Histologic Findings in Clinical Practice	96
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma	96
PPARγ Coactivator‐1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ–Dependent WNT/β‐Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis	95
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1	94
Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCC	93
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature	93
Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells	93
Endoplasmic reticulum stress in liver diseases	93
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	92
A Systematic Review of Animal Models of NAFLD Finds High‐Fat, High‐Fructose Diets Most Closely Resemble Human NAFLD	91
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	90
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma	89
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis	89
AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis	87
Getting to HBV cure: The promising paths forward	87
NAFLD‐related hepatocellular carcinoma: The growing challenge	87
Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies	86
Hypoxia‐Inducible Exosomes Facilitate Liver‐Tropic Premetastatic Niche in Colorectal Cancer	85
Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection	85
Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway	81
Impact of COVID‐19 Pandemic on Liver Transplantation and Alcohol‐Associated Liver Disease in the USA	80
Heterogeneity of HSCs in a Mouse Model of NASH	80
Local and Regional Therapies for Hepatocellular Carcinoma	80
The Use of Rifaximin in Patients With Cirrhosis	80
Reducing the Global Burden of Alcohol‐Associated Liver Disease: A Blueprint for Action	79

Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases	78
An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States	76
Effect of increased alcohol consumption during COVID‐19 pandemic on alcohol‐associated liver disease: A modeling study	75
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease	75
A revised electronic version of RUCAM for the diagnosis of DILI	73
Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer	72
Regional Differences in Human Biliary Tissues and Corresponding In Vitro–Derived Organoids	72
Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6‐Methyladenosine mRNA Methylation‐Dependent Mechanism	72
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease	71
The IKKβ‐USP30‐ACLY Axis Controls Lipogenesis and Tumorigenesis	70
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases	70
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria	70
Hydrogen Sulfide Alleviates Liver Injury Through the S‐Sulfhydrated‐Kelch‐Like ECH‐Associated Protein 1/Nuclear Erythroid 2–Related Factor 2/Low‐Density Lipoprotein Receptor–Related Protein 1 Pathway	69
Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study	69
Lysyl Oxidase‐Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis	68
Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐Year Experience in 207‐Patient Cohort	67
Therapeutic Potential of TLR8 Agonist GS‐9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators	67
Liver zonation, revisited	67
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury	67
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	67
Liver injury after SARS‐CoV‐2 vaccination: Features of immune‐mediated hepatitis, role of corticosteroid therapy and outcome	67
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis	66
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer	66
Machine perfusion in liver transplantation	66
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH	65
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC	65
Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study	64
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis	64
Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality	64
HLA‐B*35:01 and Green Tea–Induced Liver Injury	64
Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury	63
IL‐6–induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma	63
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity	62
Evolution of Systemic Therapy for Hepatocellular Carcinoma	61
The Emerging Role of B Cells in the Pathogenesis of NAFLD	61
Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID‐19): U.S. Multicenter Experience	61
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis	61
Genome‐wide Association Study and Meta‐analysis on Alcohol‐Associated Liver Cirrhosis Identifies Genetic Risk Factors	60
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation	60
Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management	60
Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study	60
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma	59
Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome	59
Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C‐C Motif Chemokine Ligand 2–Mediated Angiocrine Signaling	58
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study	58
Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation	58
IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis	58
Tumor‐derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression	58
Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers	57
Liver Cancer Immunity	57
Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell‐free DNA fragmentomics	57
Endoscopic Cyanoacrylate Injection Versus Balloon‐Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial	57
Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α	57
Functional Comparison of Interferon‐α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon‐α and Interferon‐γ Signaling	57
LSD1‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1‐Induced p62 Transcription in HCC	57
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care	56
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta‐analysis	56
Shear stress–induced cellular senescence blunts liver regeneration through Notch–sirtuin 1–P21/P16 axis	56
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients	56
Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice	56
Health disparities in chronic liver disease	56
Mechanisms of drug resistance in HCC	56
Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis	55
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma	55
Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension	55
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice	54
Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice	53
YAP‐TEAD mediates PPAR α–induced hepatomegaly and liver regeneration in mice	53
Microwave ablation versus laparoscopic resection as first‐line therapy for solitary 3–5‐cm HCC	53
Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD	53
Fatty Acid Synthase–Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD	53
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	53
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID‐19 in patients with chronic liver disease	53
DNA Methylation Profiling of Human Hepatocarcinogenesis	53
Toll‐Like Receptor 8 Agonist GS‐9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B	53
PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity	52
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications	52
Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC	52
Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!	52
Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses	52

A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	52
MiR‐125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma	51
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs	51
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy	51
Risk factors for HCC in contemporary cohorts of patients with cirrhosis	51
Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States	51
Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study	51
Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation	51
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH	51
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH	51
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease	51
HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3	50
Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	50
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD	49
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis	49
DDX17‐regulated alternative splicing that produced an oncogenic isoform of PXN‐AS1 to promote HCC metastasis	49
Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice	49
NAFLD and Alcohol‐Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040	49
Frailty, mortality, and health care utilization after liver transplantation: From the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study	49
European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children	48
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B	48
L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial	48
Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies	48
Two Faces of Neutrophils in Liver Disease Development and Progression	48
Farnesoid X Receptor Activation Impairs Liver Progenitor Cell–Mediated Liver Regeneration via the PTEN‐PI3K‐AKT‐mTOR Axis in Zebrafish	48
Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population‐Based Study of 1,355 Adults	48
Diabetes medications and risk of HCC	48
Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia	47
Hepatocyte Nuclear Factor 4α Prevents the Steatosis‐to‐NASH Progression by Regulating p53 and Bile Acid Signaling (in mice)	47
An Endoplasmic Reticulum Stress–MicroRNA‐26a Feedback Circuit in NAFLD	47
Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling	47
Intratumoral γδ T‐Cell Infiltrates, Chemokine (C‐C Motif) Ligand 4/Chemokine (C‐C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma	47
Frailty is associated with increased risk of cirrhosis disease progression and death	47
Intestinal peroxisome proliferator‐activated receptor α‐fatty acid‐binding protein 1 axis modulates nonalcoholic steatohepatitis	47
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial	47
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis	46
T‐Cell Immunoglobulin and Mucin Domain‐Containing Protein‐4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury	46
The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis	46
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease	46
Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant	46
A strategy of vascular‐targeted therapy for liver fibrosis	46
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors	46
A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis	45
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	45
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases	45
Geographical similarity and differences in the burden and genetic predisposition of NAFLD	45
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis	44
Nonalcoholic Fatty Liver Disease and Cardiac Remodeling Risk: Pathophysiological Mechanisms and Clinical Implications	44
Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial	44
Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells	44
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: A rare adverse effect?	44
Prevalence of HBV Infection, Vaccine‐Induced Immunity, and Susceptibility Among At‐Risk Populations: US Households, 2013‐2018	43
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?	43
Therapeutic efficacy of FASN inhibition in preclinical models of HCC	43
Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression	43
TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard‐of‐Care Therapy	43
Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19	43
H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen‐Activated Protein Kinase–Dependent Manner and Sponging micro	43
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim‐Sulfamethoxazole Induced Liver Injury	43
Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma	43
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System	42
Tripartite Motif‐Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β–Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation	42
Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)	42
Model for End‐Stage Liver Disease‐Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease	41
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study	41
Effect of corticosteroid dosing on outcomes in high‐grade immune checkpoint inhibitor hepatitis	41
Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis	41
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer‐Associated Fibroblasts Formed After Chronic Liver Injuries	41
Gallstones, Body Mass Index, C‐Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data	41
Gain of LINC00624 Enhances Liver Cancer Progression by Disrupting the Histone Deacetylase 6/Tripartite Motif Containing 28/Zinc Finger Protein 354C Corepressor Complex	41
Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions	41
Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer	40
A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome	40
Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling	40
Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor	39
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	39
Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments	39
Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study	39
Impact of Public Health Policies on Alcohol‐Associated Liver Disease in Latin America: An Ecological Multinational Study	39
Aging exaggerates acute‐on‐chronic alcohol‐induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1‐C/EBPα‐miRNA‐223 axis	39
Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States	38
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma	38
Functional Consequences of Metabolic Zonation in Murine Livers: Insights for an Old Story	38
Hepatic Small Ubiquitin‐Related Modifier (SUMO)–Specific Protease 2 Controls Systemic Metabolism Through SUMOylation‐Dependent Regulation of Liver–Adipose Tissue Crosstalk	38
Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling	38
TMEM9‐v‐ATPase Activates Wnt/β‐Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis	38
Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus	38
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack	37
Mutations in the V‐ATPase Assembly Factor VMA21 Cause a Congenital Disorder of Glycosylation With Autophagic Liver Disease	37
The Clinical Significance of Hepatic CD69+CD103+CD8+ Resident‐Memory T Cells in Autoimmune Hepatitis	37
Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis	37
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut‐Off Approach	37
Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium	36
Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease	36
Hepatitis B Virus–Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma	36